Macrogenics INC Schedule 13G passive stakes

Armistice Capital, LLC, along with its managing member Steven Boyd, has reported beneficial ownership of 7.88% of MacroGenics, Inc. common stock as of June 30, 2026.

Bank of America Corporation has disclosed a beneficial ownership of 4.0% in MacroGenics Inc., holding 2,556,475 shares.

Millennium Management LLC, along with affiliated entities and Israel A. Englander, has reported beneficial ownership of 3.7% of MacroGenics, Inc. common stock as of June 30, 2026.

Millennium Management LLC and Israel A. Englander have reported a 5.4% beneficial ownership stake in MacroGenics, Inc. via a Schedule 13G filing.

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 6,012,000 shares, representing 9.46% of MacroGenics, Inc.'s common stock.

Millennium Management LLC and Israel A. Englander have filed a Schedule 13G disclosing a reduction in their beneficial ownership of MacroGenics, Inc. to below the 5% threshold.

Bank of America Corporation has filed a Schedule 13G reporting a 5.1% beneficial ownership stake in MacroGenics, Inc. common stock.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in MacroGenics Inc. following an internal realignment that disaggregated reporting responsibilities.

Frazier Life Sciences and its affiliates have reported a complete divestment of their beneficial ownership in Macrogenics, Inc., holding 0.0% of common stock.

Bellevue Group AG and its subsidiary Bellevue Asset Management AG have filed an exit statement, reporting zero beneficial ownership in MacroGenics, Inc. common stock.

Wasatch Advisors LP has filed an amended Schedule 13G, disclosing a 3.1% beneficial ownership stake in MacroGenics Inc. as of September 30, 2025.

Armistice Capital and Steven Boyd report a 9.45% beneficial ownership stake in Macrogenics Inc., holding 5,960,000 shares of common stock.

Frazier Life Sciences group files an amended Schedule 13G, clarifying its beneficial ownership in Macrogenics, Inc. to 5.1% of common stock.

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 2.9% passive beneficial ownership stake in MacroGenics Inc. common stock as of June 30, 2025.

Bellevue Group AG and its subsidiary Bellevue Asset Management AG have disclosed a 15.7% passive ownership stake in MacroGenics, Inc., holding 9,929,963 shares of common stock.

BB Biotech AG and its subsidiary Biotech Target N.V. have filed an exit Schedule 13G, indicating they no longer beneficially own 5% or more of MacroGenics Inc.'s common stock.

Armistice Capital, LLC and Steven Boyd have reported a 9.98% beneficial ownership stake in MacroGenics Inc., holding 6,296,000 shares of common stock as of March 31, 2025.

Millennium Management LLC, along with Millennium Group Management LLC and Israel A. Englander, has disclosed a beneficial ownership of 2.7% of MacroGenics, Inc.'s common stock, totaling 1,724,250 shares.

RA Capital Management, L.P. and its affiliates have filed an amended Schedule 13G, reporting a complete divestment of their beneficial ownership in Macrogenics, Inc. Common Stock.

Investment firm Armistice Capital, LLC and its managing member Steven Boyd have reported a 9.99% beneficial ownership stake in biopharmaceutical company MacroGenics, Inc. as of December 31, 2024.

BB Biotech AG and its subsidiary Biotech Target N.V. have disclosed their continued beneficial ownership of 15.8% of MacroGenics Inc.'s common stock as of December 31, 2024.

Wasatch Advisors LP has reported a passive 5.6% ownership stake in biopharmaceutical company MacroGenics Inc., holding 3,488,493 shares of common stock as of December 31, 2024.